- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Endo Pharms. Inc. v. Teva Pharms. USA, Inc.
The Federal Circuit affirms the district court’s judgment that the asserted patents were not invalid and were infringed.
May 16, 2018
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Eli Lilly & Co. v. Hospira, Inc., Civ. No. 12-3460-TWP-MPB, 2018 U.S. Dist. LEXIS 100550 (S.D. Ind. June 15, 2018) (Pratt, J.)
Drug Product and Patent(s)-in-Suit: Alimta® (pemetrexed disodium); U.S. Patent No. 7,772,209 (“the ’209 patent”)
Nature of the Case and Issue(s) Presented: Lilly marketed Alimta, having the active ingredient pemetrexed disodium, as a chemotherapy drug taken in conjunction with a vitamin B12 and folic acid pretreatment. The ’209 patent taught a method for using pemetrexed disodium for chemotherapeutic treatment.
During the prosecution of the ’209 patent, Lilly narrowed the scope of its claims to only include pemetrexed disodium to avoid the prior art. Hospira made a similar chemotherapy drug, using pemetrexed ditromethamine. Hospira’s prescribing information stated that the product could be reconstituted in a saline solution. The issue before the court, and the subject of the parties’ cross motions for summary judgment, was whether this reconstituted saline solution were within the scope of the ’209 patent in light of the prosecution history. The court found in favor of Lilly and against Hospira.
Why Lilly Prevailed: Supporting its summary judgment motion, Lilly submitted expert testimony that, when mixed with a saline solution, pemetrexed ditromethamine formed pemetrexed disodium. This was because the chemical serving as the chemotherapeutic agent was pemetrexed. Because pemetrexed disassociated its ionic bond after administration, it was irrelevant whether it was initially ionically bonded to disodium or ditromethamine. Accordingly, Hospira’s product literally infringed the claims of the ’209 patent.
The court also found that Hospira induced infringement of the ’209 patent. Hospira’s product label instructed its user to administer the product in accordance with the method steps claimed by the ’209 patent. Due to this labeling, Hospira conceded that, as a matter of law, if the Court were to find its product would infringe, Hospira would induce infringement.
Related Professionals
Christopher A. Pinahs
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.